Effect of Ivermectin on Time to Resolution of Symptoms for Mild Covid-19(jamanetwork.com)
jamanetwork.com
Effect of Ivermectin on Time to Resolution of Symptoms for Mild Covid-19
https://jamanetwork.com/journals/jama/fullarticle/2777389
3 comments
Old garbage, as redrain notes, not to mention see https://jamaletter.com and/or https://c19ivermectin.com/scheim2.html https://c19ivermectin.com/scheim.html and finally https://c19ivermectin.com/lopezmedina.html
todays Ivermectin thread: https://news.ycombinator.com/item?id=27562412
From https://news.ycombinator.com/item?id=27500423
https://osf.io/u7ewz/
Lowe mentions: "Objections have been raised to that trial’s use of an oral suspension formulation, I should note.". But by reading the linked article we can see that there is much more to note:
"In the statistical analysis subsection of the article, the authors acknowledged 2 RCT issues: i) they modified the primary end point to time from randomization to complete resolution of symptoms within the 21-day follow-up period and ii) a labeling error occurred between September 29 and October 15, 2020, resulting in an unblinded protocol during this time frame."
Protocol violations in López-Medina et al.: 38 switched ivermectin (IVM) and placebo doses, failure of blinding, widespread IVM sales OTC in Cali, and nearly identical AEs for the IVM and control groups
https://alethonews.com/2021/06/09/is-there-a-problem-with-th...
>Dr. López-Medina reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, and Janssen as well as personal fees from Sanofi Pasteur during the conduct of the study. Dr. Oñate reported receiving grants from Janssen and personal fees from Merck Sharp & Dohme and Gilead outside the submitted work. Dr. Torres reported receiving nonfinancial support from Tecnoquímicas unrelated to this project during the conduct of the study. No other disclosures were reported.
https://osf.io/u7ewz/
Lowe mentions: "Objections have been raised to that trial’s use of an oral suspension formulation, I should note.". But by reading the linked article we can see that there is much more to note:
"In the statistical analysis subsection of the article, the authors acknowledged 2 RCT issues: i) they modified the primary end point to time from randomization to complete resolution of symptoms within the 21-day follow-up period and ii) a labeling error occurred between September 29 and October 15, 2020, resulting in an unblinded protocol during this time frame."
Protocol violations in López-Medina et al.: 38 switched ivermectin (IVM) and placebo doses, failure of blinding, widespread IVM sales OTC in Cali, and nearly identical AEs for the IVM and control groups
https://alethonews.com/2021/06/09/is-there-a-problem-with-th...
>Dr. López-Medina reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, and Janssen as well as personal fees from Sanofi Pasteur during the conduct of the study. Dr. Oñate reported receiving grants from Janssen and personal fees from Merck Sharp & Dohme and Gilead outside the submitted work. Dr. Torres reported receiving nonfinancial support from Tecnoquímicas unrelated to this project during the conduct of the study. No other disclosures were reported.